Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …
and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for …
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …
MJ Davies, VR Aroda, BS Collins, RA Gabbay… - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the previous consensus statements on the management of …
convened a panel to update the previous consensus statements on the management of …
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group …
Background According to current consensus guidelines for type 2 diabetes management,
bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single …
bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled …
Background Treating hyperglycaemia and obesity in individuals with type 2 diabetes using
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …
multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a …
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the …
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the previous consensus statements on the …
Diabetes convened a panel to update the previous consensus statements on the …
Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical …
L He, J Wang, F Ping, N Yang, J Huang… - JAMA internal …, 2022 - jamanetwork.com
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been widely
recommended for glucose control and cardiovascular risk reduction in patients with type 2 …
recommended for glucose control and cardiovascular risk reduction in patients with type 2 …
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised …
VR Aroda, J Aberle, L Bardtrum, E Christiansen… - The Lancet, 2023 - thelancet.com
Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …
to investigate a new formulation of oral semaglutide at higher investigational doses versus …
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Background Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor
agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and …
agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and …
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
I Caruso, L Di Gioia, S Di Molfetta, A Cignarelli… - …, 2023 - thelancet.com
Background Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …